InteRNA to Present Preclinical Proof-of-Concept Data on Lead microRNA Candidate INT-1B3 at 2018 AACR Annual Meeting

UTRECHT, Netherlands--()--InteRNA Technologies announced today that the company will present a poster on its lead microRNA development candidate INT-1B3 at the American Association for Cancer Research (AACR) Annual Meeting, to be held in Chicago, IL, on April 14-18, 2018. The proof-of-concept data highlight INT-1B3’s unique ability to target multiple hallmarks of cancer as a single agent, demonstrating immune system activation, tumor regression and pronounced long term immunity. InteRNA will announce the complete results through a press release following the presentation.

Poster Information:
Title: Pharmacologic profile of INT-1B3: a novel synthetic microRNA 193a-3p mimic for therapeutic intervention in Oncology (Abstract #4405)
Presenters: Drs. Sanaz Yahyanejad (Senior Research Scientist) and Michel Janicot (Chief Development Officer)
Session Name: Molecular and Cellular Biology / Genetics – MicroRNA Therapeutics
Date & Time: Tuesday, April 17, 2018; 1:00 pm -5:00 pm Central Standard Time
Location: McCormick Place South, Exhibit Hall A, Poster Section 19, Poster Board Number:6

Link to AACR Conference Abstract:
http://www.abstractsonline.com/pp8/#!/4562/presentation/5896

About InteRNA Technologies
InteRNA is developing potent microRNA drug candidates designed to mount a coordinated anti-cancer attack by engaging multiple signal transduction targets simultaneously. The company’s focused anti-cancer pipeline has demonstrated proof-of-concept in key in vivo models showing effective target engagement and strong anti-tumor response. Lead candidate INT-1B3 induces immune system activation, tumor regression and pronounced long-term immunity by targeting the adenosine-dependent signaling pathways as well as key targets involved in tumor cell proliferation and survival, and cell-cycle modulation. Founded by Aglaia Oncology Fund, the company aims to harness its expertise in RNA delivery technologies and manufacturing to bring microRNA therapeutics to cancer patients.

Contacts

InteRNA Technologies
Roel Schaapveld, CEO
Phone: +31 (0)24 352 96 33
E-mail: schaapveld@interna-technologies.com
or
Trophic Communications
Stephanie May or Joanne Tudorica
Phone: +49 2388 7733 30 or +49 171 185 56 82
E-mail: may@trophic.eu or tudorica@trophic.eu

Social Media Profiles

Contacts

InteRNA Technologies
Roel Schaapveld, CEO
Phone: +31 (0)24 352 96 33
E-mail: schaapveld@interna-technologies.com
or
Trophic Communications
Stephanie May or Joanne Tudorica
Phone: +49 2388 7733 30 or +49 171 185 56 82
E-mail: may@trophic.eu or tudorica@trophic.eu